News releases

A few years ago, this 21-year-old patient began experiencing heart palpitations, black spots in her vision, and a loss of strength often at the end of a workday or when climbing stairs. She quickly realized something was wrong and consulted a doctor, who detected a heart murmur. Further tests later confirmed the diagnosis of obstructive hypertrophic cardiomyopathy (HCM).

The Immunoscience Academy, an educational platform supported by Bristol Myers Squibb, has launched the “Immunotherapy in Practice” podcast. The four-episode series helps oncology professionals stay ahead of rapid developments in cancer treatment.

 

This podcast is designed for oncology specialists who seek to stay updated with the latest scientific insights and practical approaches in immunotherapy.

Alphonse has always faced life with optimism, yet for as long as he could remember, something didn't quite feel right. At the age of 25, doctors detected a heart murmur, but Alphonse continued living his life with few changes.

Willem, 38, had a very active childhood and a passion for football until a routine check-up changed everything. A doctor discovered a heart murmur and further tests confirmed a diagnosis of obstructive hypertrophic cardiomyopathy (oHCM). Willem was forced to give up sports entirely, which was a challenging adjustment at first. Yet, with the right medical support, he learned to adapt and embrace a different but still active lifestyle.

Cardiomyopathies Matter, a collaborative initiative funded by Bristol Myers Squibb, aims to bring together policymakers, experts, societal stakeholders and patients to engage in a constructive exchange on cardiomyopathies. This group of diseases is often overlooked in public discussions. In order to raise awareness of the realities of this disease, Cardiomyopathies Matter is launching a podcast, in French and Dutch. 

The 10th edition of the Country 2 Country 4 Cancer (C2C4C) cycle race is in full swing, and once again Bristol Myers Squibb employees from Belgium and the Netherlands are taking part.

 

This year, six employees from Belgium and the Netherlands will take on the challenge and contribute to this joint effort: Virginie Tytgadt, Frederik Bogaert, Alex Romano, Marion Oudshoorn, Monique Melis and Jeroen Baghus.

For Johan, 66, shortness of breath and increased sweating were only minor inconveniences, which he quickly dismissed or attributed to external factors. It was only by chance that he discovered during a routine check-up that he had hypertrophic cardiomyopathy (HCM). His journey illustrates how easily this often inherited heart disease can go unnoticed and emphasises the importance of early diagnosis.

The outlook for patients with advanced melanoma has significantly improved over the past ten years thanks to innovations in immunotherapy and targeted therapy. During a study day organized by Melanoompunt vzw, experts and survivors discussed the impact of these treatments and the challenges that lie ahead. Despite groundbreaking progress, continued medical innovation remains crucial to further improve survival rates.

Hematologic malignancies are complex, with over 100 types, each requiring a tailored treatment approach. Despite scientific advances in blood cancer treatment, many blood disorders still lack cures or new therapies. BMS is leading innovations in hematology and cell therapy, focusing on personalized care, novel modalities, and patient-centered approaches. With over 25 programs in development, BMS is committed to advancing treatments and improving outcomes for patients, leveraging technologies like AI and fostering collaborations across the healthcare ecosystem.

We have been awarded the esteemed Prix Galien Award for Best Pharmaceutical Agent, recognizing groundbreaking healthcare innovations.

With Bristol Myers Squibb, we celebrated this achievement, often called the "Nobel Prize for medical innovation." This award, originating in France, is now recognized in 15 countries.

Congratulations to all nominees and participants who share our dedication to advancing medical science.

Meet José, a patient who brings to life the daily challenges of living with Hypertrophic Cardiomyopathy (HCM). At Bristol Myers Squibb, we are dedicated to raising awareness and enhancing the management of this often unnoticed inherited heart condition. José's story underscores the critical importance of early diagnosis, ongoing research, and the need for improved treatments.

We invite you to listen carefully to patient experiences and unite with us to create a brighter tomorrow for all affected by this condition.

Every day, we focus on supporting people with psoriasis, one of Europe's most common skin conditions. Psoriasis is more than a skin condition; it is a chronic disease that brings daily challenges and affects both the body and the mind.

In our latest testimonial video, Ann-Sophie from Belgium shares her experiences living with psoriasis. From the daily struggles to her hopes for the medical future. Her story is one of many, but every story is unique and deserves to be heard.

From 16 to 18 September 2023, five Bristol Myers Squibb employees from Belgium and the Netherlands participated in the eighth edition of the Country 2 Country 4 Cancer (C2C4C) bike race. After months of intensive training, they will give their best during three cycling stages from Paris, across Amiens and Calais, to Dover to finish in Uxbridge (London).

On March 8^th, we celebrated International Women’s Day. The focus this year is on gender equity and celebrating women telling their stories. The B-NOW Belgian Chapter was thrilled to invite BMS Braine-l’Alleud-based employees to its first Lunch & Learn session of the year. 

Cancer treatments are getting better, more diverse and more numerous. Although we still die from cancer, we are also increasingly recovering from it... Research, pharmaceutical companies, governments and private individuals are joining forces to fight cancer together.